A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Active, not recruiting · NCT06777316 · Registry updated 2026-04-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors | Cirrhosis, Familial, with Pulmonary Hypertension, Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-04-17 | NCT06777316 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cogent Biosciences, Inc. | 7 |
13 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fox Chase Cancer Center | Philadelphia | United States | 259 |
| Huntsman Cancer Institute - University of Utah | Salt Lake City | United States | 7 |
| Massachusetts General Hospital | Boston | United States | 1015 |
| Mayo Clinic Jacksonville | Jacksonville | United States | 67 |
| Mayo Clinic Rochester | Rochester | United States | 133 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| Moffitt Cancer Center | Tampa | United States | 523 |
| Princess Margaret Cancer Centre - UHN | Toronto | Canada | 1 |
| Stanford Cancer Institute | Palo Alto | United States | 11 |
| Taussig Cancer Center - Cleveland Clinic | Cleveland | United States | 1 |
| Tennessee Oncology | Nashville | United States | 77 |
| The Christ Hospital | Cincinnati | United States | 81 |
| University of Chicago Medicine Comprehensive Cancer Center | Chicago | United States | 26 |